title: CXC chemokine expression profiles in aqueous humor of patients with different clinical entities of endogenous uveitis.
abstract: Aqueous humor (AH) samples from patients with Behçet's disease (BD) (n=29), Vogt-Koyanagi-Harada (VKH) disease (n=21), and HLA-B27-associated uveitis (n=8), and 42 control patients were assayed for the neutrophil chemoattractants CXCL1/GRO-α and CXCL8/IL-8 and the lymphocyte chemoattractants CXCL9/MIG, CXCL10/IP-10 and CXCL12/SDF-1 with the use of a multiplex chemokine assay. Chemokine levels except SDF-1 were significantly higher in the 3 disease groups than in normal controls. Considering all patients, mean GRO-α levels were 15-fold higher than IL-8 levels and mean IP-10 levels were 22-fold higher than MIG levels. In patients with the same disease activity, AH levels of GRO-α and IP-10 were significantly higher in patients with BD than in patients with VKH disease and HLA-B27-associated uveitis (p=0.0474; p<0.001, respectively). These data suggest that GRO-α and IP-10 are the predominant CXC chemokines involved in neutrophil and activated T lymphocyte chemoattraction in endogenous uveitis, particularly in BD.
authors.affiliation: Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
authors.forename: Ahmed M Abu
authors.initials: AM
authors.lastname: El-Asrar
authors.forename: Saleh S
authors.initials: SS
authors.lastname: Al-Obeidan
authors.forename: Dustan
authors.initials: D
authors.lastname: Kangave
authors.forename: Karel
authors.initials: K
authors.lastname: Geboes
authors.forename: Ghislain
authors.initials: G
authors.lastname: Opdenakker
authors.forename: Jo
authors.initials: J
authors.lastname: Van Damme
authors.forename: Sofie
authors.initials: S
authors.lastname: Struyf
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D001082:Aqueous Humor / Q000276:immunology / Q000378:metabolism*; D001528:Behcet Syndrome / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism*; D015415:Biomarkers / Q000032:analysis; D016022:Case-Control Studies; D054360:Chemokine CXCL1 / Q000096:biosynthesis* / Q000276:immunology; D054357:Chemokine CXCL10 / Q000096:biosynthesis* / Q000276:immunology; D054370:Chemokine CXCL9 / Q000096:biosynthesis* / Q000276:immunology; D005260:Female; D015870:Gene Expression; D015796:HLA-B27 Antigen / Q000032:analysis / Q000276:immunology; D006801:Humans; D007118:Immunoassay; D008213:Lymphocyte Activation / Q000276:immunology; D008214:Lymphocytes / Q000276:immunology / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000276:immunology / Q000378:metabolism; D014605:Uveitis / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism*; D014607:Uveomeningoencephalitic Syndrome / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism*
chemical_list: D000305:Adrenal Cortex Hormones; D015415:Biomarkers; C475829:CXCL1 protein, human; C114753:CXCL10 protein, human; C080810:CXCL9 protein, human; D054360:Chemokine CXCL1; D054357:Chemokine CXCL10; D054370:Chemokine CXCL9; D015796:HLA-B27 Antigen